C4 Therapeutics, Inc.
NASDAQ:CCCCBiotechnology
+$0.08 today
- Market cap
- $332.23M
- Beta
- 2.93
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.82
Volume 2.84M
Average 2.76M
CCCC Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
C4 Therapeutics, Inc.NASDAQ: CCCC
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin narrows to -451.6%
Operating margin was -451.6% in Q1 FY2026, down 48.7 pp from a year earlier. On a trailing-twelve-month basis it was -326.6%, down 33.6 pp year over year. Over 3 fiscal years it widened by 125.9 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 4 analysts of -223.0% for the fiscal year ending Dec 2026, up from -290.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -451.6%-241.5 pp QoQ
- Last fiscal yearDec 2025
- -290.7%+45.5 pp YoY
- LTMMar 2026
- -326.6%-33.6 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -290.7%
- Year-over-year change
- +45.5pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -290.7% | +45.5pp |
| FY2024 | 2024-12-31 | -336.1% | +333.7pp |
| FY2023 | 2023-12-31 | -669.8% | -253.3pp |
| FY2022 | 2022-12-31 | -416.6% | -237.2pp |
| FY2021 | 2021-12-31 | -179.4% | — |
Operating Margin vs competitors
How CCCC compares with its peers on the latest reported figures
- CCCC's LTM Mar 2026 operating margin of -326.6% is the 4th highest of the 7 companies compared; the peer median is -788.9%.
- Its year-over-year change of -33.6 pp is the 3rd highest of 6, against a peer median of -190.5 pp.
- Over three fiscal years its change of +125.9 pp compares with a peer median of -60.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -33.2% | +101.6 pp | -29.3 pp | |
| LTM Mar 2026 | -200.3% | +64.4 pp | -338.0 pp | |
| LTM Mar 2026 | -319.2% | -190.5 pp | -92.2 pp | |
| LTM Mar 2026 | -326.6% | -33.6 pp | +125.9 pp | |
| LTM Mar 2026 | -1258.6% | -398.8 pp | +34.1 pp | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -2112.4% | -588.3 pp | +1124.5 pp |
| LTM Mar 2026 | -3669.4% | — | -2848.9 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding CCCC) | -788.9% | -190.5 pp | -60.8 pp | |
Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 45.79M | 31.1M | 20.76M | 35.58M | 35.95M |
| Cost of Revenue | 0 | 0 | 7.74M | 0 | 7.98M |
| Gross Profit | 45.79M | 31.1M | 13.02M | 35.58M | 27.97M |
| Gross Margin | 100.0% | 100.0% | 62.7% | 100.0% | 77.8% |
| Research & Development | 94.67M | 117.84M | 117.71M | 110.64M | 104.24M |
| Selling, General & Admin | 33.25M | 42.79M | 42.08M | 42.12M | 36.2M |
| Operating Expenses | 127.92M | 160.63M | 152.05M | 155.2M | 132.46M |
| Depreciation & Amortization | 1.49M | 1.68M | 7.74M | 1.82M | 1.96M |
| EBITDA | (80.26M) | (124.28M) | (122.1M) | (103.37M) | (102.91M) |
| EBITDA Margin | -175.3% | -399.7% | -588.3% | -290.5% | -286.3% |
| Operating Income | (82.13M) | (129.53M) | (139.03M) | (119.61M) | (104.49M) |
| Operating Margin | -179.4% | -416.6% | -669.8% | -336.1% | -290.7% |
| Interest Income | 387K | 3.58M | 9.81M | 14.43M | 10.35M |
| Interest Expense | 2.15M | 2.22M | 1.37M | 0 | 0 |
| Other Income / Expenses | (1.76M) | 1.36M | 7.82M | 14.43M | (384K) |
| Income Before Tax | (83.89M) | (128.18M) | (131.21M) | (105.19M) | (104.87M) |
| Pre-Tax Margin | -183.2% | -412.2% | -632.2% | -295.6% | -291.7% |
| Income Tax Expense | 0 | 0 | 1.28M | 131K | 121K |
| Net Income | (83.89M) | (128.18M) | (132.49M) | (105.32M) | (104.99M) |
| Net Margin | -183.2% | -412.2% | -638.3% | -296.0% | -292.1% |
| EPS (Basic) | (1.82) | (2.62) | (2.67) | (1.52) | (1.27) |
| EPS (Diluted) | (1.82) | (2.62) | (2.67) | (1.52) | (1.27) |
| Weighted Avg Shares | 46.04M | 48.86M | 49.64M | 69.37M | 82.89M |
| Weighted Avg Shares (Diluted) | 46.04M | 48.86M | 49.64M | 69.37M | 82.89M |
C4 Therapeutics, Inc.
NASDAQ:CCCC
Intrinsic Alpha fair value
Locked
Current Price
$2.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.